title: The RAF inhibitor paradox revisited.
abstract: The success of the RAF protein kinase inhibitor vemurafenib for the treatment of BRAF mutant metastatic melanoma has produced another poster child for the promise of personalized medicine. However, the results of a recent study also reveal unexpected pitfalls in the application of signal transduction-targeted therapies.
authors.affiliation: Department of Radiation Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. adricox@med.unc.edu
authors.forename: Adrienne D
authors.initials: AD
authors.lastname: Cox
authors.forename: Channing J
authors.initials: CJ
authors.lastname: Der